Disturbing microtubule-endoplasmic reticulum dynamics by gold nanoclusters for improved triple-negative breast cancer treatment

被引:1
|
作者
Cao, Kai [1 ]
Luo, Kaidi [1 ]
Zheng, Yichen [1 ]
Xue, Liyuan [1 ]
Huo, Wendi [1 ]
Ruan, Panpan [1 ]
Wang, Yuchen [1 ]
Xue, Yilin [1 ]
Yao, Xiuxiu [1 ]
Xia, Dongfang [1 ]
Gao, Xueyun [1 ]
机构
[1] Beijing Univ Technol, Coll Chem & Life Sci, Ctr Excellence Environm Safety & Biol Effects, Dept Chem, Beijing 100124, Peoples R China
基金
中国国家自然科学基金;
关键词
ADJUVANT DOCETAXEL; PROSTATE; COMBINATION; APOPTOSIS; TAXANES; CELLS;
D O I
10.1039/d4tb01492h
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Microtubules are highly dynamic structures, and their dynamic instability is indispensable for not only cell growth and movement, but also stress responses, such as endoplasmic reticulum (ER) stress. Docetaxel, a microtubule targeting agent (MTA), is the first-line drug for cancer treatment by simultaneously promoting microtubule dysregulation- and ER stress-induced cell death. However, it also causes adverse effects and drug resistance, especially in triple-negative breast cancer (TNBC) with a poor prognosis and high mortality rate. In this study, we developed a peptide-templated gold nanocluster, namely GA. GA significantly sensitizes TNBC cells to docetaxel, causing severe cell death. This effect is further validated by a 3D tumor spheroid model. Mechanistically, GA disrupted microtubule dynamic instability, meanwhile promoting PERK-mediated ER stress. Interestingly, ER stress inhibitors profoundly suppressed microtubule dysregulation, suggesting a retrograde regulation of ER stress on microtubules. In vivo, the combined administration of docetaxel and GA significantly suppresses tumor growth while docetaxel alone cannot. GA similarly elevated the level of caspases and PERK within tumors as in vitro. Importantly, GA treatment also profoundly promoted the production of anti-tumor inflammatory cytokines. Collectively, we developed an ER-microtubule regulatory nanomaterial that enhanced the therapeutic effect of docetaxel by elevating tumor cell death and anti-tumor cytokine production, providing a potential supplemental strategy for TNBC treatment. Gold nanocluster GA acts as a docetaxel sensitizer to promote ER stress and microtubule dysregulation, leading to significant tumor cell death and promoting anti-tumor cytokine production in treating triple-negative breast cancer.
引用
收藏
页码:11648 / 11658
页数:11
相关论文
共 50 条
  • [41] Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment
    Wu, Xinhong
    Yuan, Feng
    Guo, Liantao
    Gao, Dongcheng
    Zheng, Weijie
    Chen, Chuang
    Zheng, Hongmei
    Liu, Jianhua
    BMC CANCER, 2025, 25 (01)
  • [42] The treatment role of Cyperus rotundus L. to triple-negative breast cancer cells
    Wang, Fukai
    Song, Xiang
    Ma, Shuangshuang
    Liu, Chenyu
    Sun, Xiaohui
    Wang, Xinzhao
    Liu, Zhaoyun
    Liang, Dong
    Yu, Zhiyong
    BIOSCIENCE REPORTS, 2019, 39
  • [43] Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study
    Reinhold, William C.
    Marangoni, Elisabetta
    Elloumi, Fathi
    Montagne, Remi
    Varma, Sudhir
    Wang, Yanghsin
    Rezai, Keyvan
    Morriset, Ludivine
    Dahmani, Ahmed
    El Botty, Rania
    Huguet, Lea
    Mizunuma, Makito
    Takebe, Naoko
    Huguet, Samuel
    Luna, Augustin
    Pommier, Yves
    CANCER RESEARCH COMMUNICATIONS, 2025, 5 (02): : 375 - 388
  • [44] In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
    Perez-Pena, Javier
    Serrano-Heras, Gemma
    Carlos Montero, Juan
    Corrales-Sanchez, Veronica
    Pandiella, Atanasio
    Ocana, Alberto
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1823 - 1833
  • [45] RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer
    My-my Huynh
    Jayanthan, Aarthi
    Pambid, Mary Rose
    Los, Gerrit
    Dunn, Sandra E.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (01) : 1 - 5
  • [46] Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
    Andre, F.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2012, 23 : 46 - 51
  • [47] Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer
    Salahuddin, Ahmad
    Ghanem, Heba
    Omran, Gamal A.
    Helmy, Maged Wasfy
    MEDICAL ONCOLOGY, 2022, 39 (10)
  • [48] Synergistic Action of Benzyl Isothiocyanate and Sorafenib in a Nanoparticle Delivery System for Enhanced Triple-Negative Breast Cancer Treatment
    Wang, Qi
    Cheng, Nan
    Wang, Wei
    Bao, Yongping
    CANCERS, 2024, 16 (09)
  • [49] Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer
    Doddapaneni, Ravi
    Patel, Ketan
    Owaid, Ibtisam Hasan
    Singh, Mandip
    DRUG DELIVERY, 2016, 23 (04) : 1232 - 1241
  • [50] Pharmacological Mechanism of Mume Fructus in the Treatment of Triple-Negative Breast Cancer Based on Network Pharmacology
    Yin, Lei
    Qi, Yan
    Jiang, Yuting
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2024, 196 (11) : 7974 - 7993